文献速递免疫规划传染病防控与疫情报告

基于复制子的COVID-19候选疫苗由烟草花叶病毒样颗粒递送

A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
PubMed 文献 · Vaccine · 2025-03-31

研究开发了基于烟草花叶病毒(TMV)的mRNA疫苗递送平台,将表达SARS-CoV-2奥密克戎株受体结合域(RBD)的自扩增Nodamura复制子包裹于TMV衣壳蛋白中。体外实验证实哺乳动物细胞中可递送自扩增mRNA、扩增转基因并表达RBD。小鼠免疫后产生RBD特异性IgG抗体,体外中和试验显示可中和SARS-CoV-2。

要点

  • TMV衣壳蛋白包装表达奥密克戎RBD的自扩增Nodamura复制子,形成纳米颗粒疫苗。
  • 细胞实验证实自扩增mRNA递送、转基因扩增及RBD表达。
  • 小鼠免疫后产生RBD特异性IgG,体外中和试验显示可中和SARS-CoV-2。

核心结论

  • 基于TMV的纳米技术平台无需超低温冰箱储存或分发,体外组装方法提供即插即用能力以快速适应新毒株或疾病。
  • 通过分子农业技术在植物中生产和自组装候选疫苗的机会存在,可能实现区域生产供区域使用,并可能为资源较少地区做出贡献。

研究设计与样本

  • 研究使用纯化的TMV衣壳蛋白包装表达SARS-CoV-2奥密克戎株RBD的自扩增Nodamura复制子,复制子构建体包含TMV的组装起始序列以用于包封和mRNA稳定化。
  • 纳米颗粒疫苗通过体外组装纯化TMV衣壳蛋白和体外转录的mRNA盒获得。
  • 细胞实验确认自扩增mRNA疫苗的递送、转基因扩增和靶蛋白RBD在哺乳动物细胞中的表达。
  • 小鼠免疫后产生RBD特异性IgG抗体,使用体外中和试验证明可中和SARS-CoV-2。

主要发现

  • 细胞实验确认自扩增mRNA疫苗的递送、转基因扩增和靶蛋白RBD在哺乳动物细胞中的表达。
  • 小鼠免疫产生RBD特异性IgG抗体,体外中和试验显示可中和SARS-CoV-2。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic highlights the opportunity for mRNA vaccines and their nanotechnology carriers to make an impact as a countermeasure to infectious disease. As alternative to the synthetic lipid nanoparticles or mammalian viruses, we developed a tobacco mosaic virus (TMV)-based mRNA vaccine delivery platform. Specifically, purified coat protein from TMV was used to package a self-amplifying Nodamura replicon expressing the receptor binding domain (RBD) from the Omicron strain of SARS-CoV-2. The replicon construct contains the origin of assembly sequence from the tobacco mosaic virus (TMV) for encapsulation and mRNA stabilization. The nanoparticle vaccine was obtained through in vitro assembly using purified TMV coat proteins and in vitro transcribed mRNA cassettes. Cell assays confirmed delivery of self-amplifying mRNA vaccine, amplification of the transgene and expression of the target protein, RBD, in mammalian cells. Immunization of mice yielded RBD-specific IgG antibodies that demonstrated neutralization of SARS-CoV-2 using an in vitro neutralization assay. The TMV platform nanotechnology does not require ultralow freezers for storage or distribution; and the in vitro assembly method provide 'plug-and-play' to adapt the vaccine formulation rapidly as new strains or diseases emerge. Finally, opportunity exists to produce and self-assemble the vaccine candidate in plants through molecular farming techniques, which may allow production in the region-for the region and could make a contribution to less resourced areas of the world.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Karan S, Opdensteinen P, Ma Y, et al. A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles. Vaccine. 2025. PMID: 40168732. doi:10.1016/j.vaccine.2025.127063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。